TY - JOUR
T1 - Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease. The PEACE Trial
AU - Omland, Torbjørn
AU - Sabatine, Marc S.
AU - Jablonski, Kathleen A.
AU - Rice, Madeline Murguia
AU - Hsia, Judith
AU - Wergeland, Ragnhild
AU - Landaas, Sverre
AU - Rouleau, Jean L.
AU - Domanski, Michael J.
AU - Hall, Christian
AU - Pfeffer, Marc A.
AU - Braunwald, Eugene
PY - 2007/7/17
Y1 - 2007/7/17
N2 - Objectives: The purpose of this study was to assess the association between B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and the incidence of specific cardiovascular events in low-risk patients with stable coronary disease, the incremental prognostic information obtained from these two biomarkers compared with traditional risk factors, and their ability to identify patients who may benefit from angiotensin-converting enzyme (ACE) inhibition. Background: The prognostic value of BNPs in low-risk patients with stable coronary artery disease remains unclear. Methods: Baseline plasma BNP and NT-proBNP concentrations were measured in 3,761 patients with stable coronary artery disease and preserved left ventricular function participating in the PEACE (Prevention of Events With Angiotensin-Converting Enzyme Inhibition) study, a placebo-controlled trial of trandolapril. Multivariable Cox regression was used to assess the association between natriuretic peptide concentrations and the incidence of cardiovascular mortality, fatal or nonfatal myocardial infarction, heart failure, and stroke. Results: The BNP and NT-proBNP levels were strongly related to the incidence of cardiovascular mortality, heart failure, and stroke but not to myocardial infarction. In multivariable models, BNP remained associated with increased risk of heart failure, whereas NT-proBNP remained associated with increased risk of cardiovascular mortality, heart failure, and stroke. By C-statistic calculations, BNP and NT-proBNP significantly improved the predictive accuracy of the best available model for incident heart failure, and NT-proBNP also improved the model for cardiovascular death. The magnitude of effect of ACE inhibition on the likelihood of experiencing cardiovascular end points was similar, regardless of either BNP or NT-proBNP baseline concentrations. Conclusions: In low-risk patients with stable coronary artery disease and preserved ventricular function, BNPs provide strong and incremental prognostic information to traditional risk factors.
AB - Objectives: The purpose of this study was to assess the association between B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and the incidence of specific cardiovascular events in low-risk patients with stable coronary disease, the incremental prognostic information obtained from these two biomarkers compared with traditional risk factors, and their ability to identify patients who may benefit from angiotensin-converting enzyme (ACE) inhibition. Background: The prognostic value of BNPs in low-risk patients with stable coronary artery disease remains unclear. Methods: Baseline plasma BNP and NT-proBNP concentrations were measured in 3,761 patients with stable coronary artery disease and preserved left ventricular function participating in the PEACE (Prevention of Events With Angiotensin-Converting Enzyme Inhibition) study, a placebo-controlled trial of trandolapril. Multivariable Cox regression was used to assess the association between natriuretic peptide concentrations and the incidence of cardiovascular mortality, fatal or nonfatal myocardial infarction, heart failure, and stroke. Results: The BNP and NT-proBNP levels were strongly related to the incidence of cardiovascular mortality, heart failure, and stroke but not to myocardial infarction. In multivariable models, BNP remained associated with increased risk of heart failure, whereas NT-proBNP remained associated with increased risk of cardiovascular mortality, heart failure, and stroke. By C-statistic calculations, BNP and NT-proBNP significantly improved the predictive accuracy of the best available model for incident heart failure, and NT-proBNP also improved the model for cardiovascular death. The magnitude of effect of ACE inhibition on the likelihood of experiencing cardiovascular end points was similar, regardless of either BNP or NT-proBNP baseline concentrations. Conclusions: In low-risk patients with stable coronary artery disease and preserved ventricular function, BNPs provide strong and incremental prognostic information to traditional risk factors.
UR - http://www.scopus.com/inward/record.url?scp=33947330983&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2007.03.038
DO - 10.1016/j.jacc.2007.03.038
M3 - Article
C2 - 17631211
AN - SCOPUS:33947330983
SN - 0735-1097
VL - 50
SP - 205
EP - 214
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 3
ER -